J Korean Med Sci.  2016 Jan;31(1):33-38. 10.3346/jkms.2016.31.1.33.

Utilization Patterns of Coagulation Factor Consumption for Patients with Hemophilia

• Lee SO
• Yu SY

• KMID: 2359989
• DOI: http://doi.org/10.3346/jkms.2016.31.1.33

Abstract

Hemophilia is a serious rare disease that requires continuous management and treatment for which the medicine is costly at the annual average of 100 million KRW for an individual. The aim of this study was to investigate trends in the utilization of coagulation factor (CF) used for hemophilia treatment using the National Health Insurance database from 2010 to 2013 in Korea and compare the utilization of CF with other countries. The consumption of CF per capita (IU) in Korea was not more than other countries with similar income to Korea. However, CF usage per patient IU was higher because the prevalence rate of hemophilia in Korea was lower than in other countries while the number of serious patients was much more. Therefore, it is difficult to say that the consumption of hemophilia medicine in Korea is higher than that in other countries. The consumption and cost of hemophilia medicine in Korea is likely to increase due to the increased utilization of expensive bypassing agents and the widespread use of prophylaxis for severe hemophilia. Even during the research period, it increased slightly and other countries show a similar trend. Thus, hemophilia patient management should accompany active monitoring on the health and cost outcomes of pharmaceutical treatment in the future. This study is expected to contribute to further insight into drug policies for other countries that face similar challenges with high price pharmaceuticals.

Keyword

Hemophilia; Coagulation Factor; Utilization; Cost

MeSH Terms

Adolescent
Adult
Aged
Blood Coagulation Disorders, Inherited/*drug therapy/*economics/pathology
Blood Coagulation Factors/*therapeutic use
Child
Child, Preschool
Databases, Factual
Female
Humans
Infant
Infant, Newborn
Male
Middle Aged
National Health Programs/statistics & numerical data
Republic of Korea
Severity of Illness Index
Young Adult
Blood Coagulation Factors

Figure

• 

  Fig. 1 Comparison of coagulation factor consumption with other high income countries. Other high income countries are whose gross national income (GNI) is larger than 12,196 USD and their data were obtained from the annual global survey (2012) of the World Federation of Hemophilia (WFH).

• 

  Fig. 2 Comparison of the ratio by severity level (severe, moderate, mild from bottom) for hemophilia patients with other high income countries. Other high income countries are whose gross national income (GNI) is larger than 12,196 USD and their data were obtained from the Annual Global Survey (2012) of the World Federation of Hemophilia (WFH). WFH, World Federation of Haemophilia; FVIII, Coagulation factor VIII; FIX, Coagulation factor IX.

Reference

1. The Korean Society of Hematology. Yoon H. Manual for the Management of Hemophilia (2nd edition). Seoul: The Korean Society of Hematology;2012.

2. Yoon HJ. Treatment of bleeding in hemophilia. J Korean Med Assoc. 2007; 50:815–822.

3. Centers for Disease Control and Prevention. Hemophilia. 2014. updated 2014. accessed on 6 May 2014. Available at http://www.cdc.gov/ncbddd/hemophilia/.

4. Kang HS, Kim WO, Song YA. Health problem and joint bleeding, limitation according to severity in patients with Hemophlia. J Rheumatol Health. 2004; 11:119–126.

5. Kang H, KIM W, Yoo M, Choi J. Treatment and characteristics related to patients with hemophilia. J Rheumatol Health. 2006; 13:119–129.

6. Kim WO, Kang HS, Song YA. Factors influencing on quality of life in patients with hemophilia. J Korean Acad Adult Nurs. 2006; 18:71–80.

7. Yoo KY, Kim SK, Kwon SS, Park SK, Yoon HJ, Lee KS, Hwang TJ, Choi YM, Lee SY. Life expectancy of Korean haemophiliacs, 1991-2012. Haemophilia. 2014; 20:e356–e358.

8. Park K, Park J, Kim M, Kim T. Depression in family members of hemophiliac patients. Clin Exp Thromb Hemost. 2014; 1:22–26.

9. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia. 2012; 18:276–283.

10. Valentino LA, Pipe SW, Tarantino MD, Ye X, Xiong Y, Luo MP. Healthcare resource utilization among haemophilia A patients in the United States. Haemophilia. 2012; 18:332–338.

11. Yan YH, Kung CM. Investigated the hospital utilization and medical resource usage of haemophilia A and B in Taiwan: 2001-2010. Health. 2013; 5:1–8.

12. Arnold DM, Webert KE, Carruthers J, Almonte T, Decker K, Seroski W, Reed J, Chan AK, Pai M, Walker I. Trends in the utilization and wastage of coagulation factor concentrates: the application of a regional tracking programme. Haemophilia. 2007; 13:271–278.

13. National Health Insurance Service. Kang Y, Kim J. National Health Insurance Statistical Yearbook 2012. Seoul: 2013.

14. Statictics Korea. Korea Statistifcal Information Service: Population Projections 2013. accessed on 15 April 2014. Available at http://kosis.kr/statisticsList/statisticsList_01List.jsp?vwcd=MT_ZTITLE&parentId=A.

15. World Federation of Hemophilia. World Federation of Hemophilia Report on the Annual Global Survey 2012. 2013. accessed on 6 May 2014. Available at http://www.wfh.org/en/annual-report.

16. Duncan N, Roberson C, Lail A, Donfield S, Shapiro A. A haemophilia disease management programme targeting cost and utilization of specialty pharmaceuticals. Haemophilia. 2014; 20:519–526.

17. O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia. 2013; 19:e239–e247.

18. Jackson SC, Yang M, Minuk L, St-Louis J, Sholzberg M, Card R, Iorio A, Poon MC. Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B. Haemophilia. 2014; 20:e199–e204.

19. Yoo KY. Hemophilia. Korean J Pediatr. 2006; 49:821–829.

20. Park YS. Recent advance of pharmacotherapy in hemophilia. J Korean Med Assoc. 2009; 52:1201–1206.

21. Kim KY, Yang CH, Cho MJ, Lee M. Comprehensive clinical and statistical analysis of hemophilia in Korea. J Korean Med Sci. 1988; 3:107–115.

22. Korean Hemophilia Foundation. Hemophilia Annual Report (2013). Seoul;2014. p. 17–23.

23. Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia. 2012; 18:e140–e153.

24. Canadian Hemophilia Society. Factor Replacement Therapy. 2014. accessed on 17 April 2014. Available at http://www.hemophilia.ca/en/about-the-chs/public-affairs/chs-policy-on-blood--blood-products-and-their-alternatives/factor-replacement-therapy/.

25. Indiana Hemophilia & Thrombosis Center. Disease & Care Management. 2014. accessed on 17 April 2014. Available at http://www.ihtc.org/payors/disease-care-management/.

26. Khleif AA, Rodriguez N, Brown D, Escobar MA. Utilization patterns and associated costs of factor assistance programmes among persons with haemophilia: a single institution review. Haemophilia. 2012; 18:e95–e100.

27. Soucie JM, Symons J 4th, Evatt B, Brettler D, Huszti H, Linden J. Hemophilia Surveillance System Project Investigators. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia. 2001; 7:198–206.

28. Soucie JM, Nuss R, Evatt B, Abdelhak A, Cowan L, Hill H, Kolakoski M, Wilber N. The Hemophilia Surveillance System Project Investigators. Mortality among males with hemophilia: relations with source of medical care. Blood. 2000; 96:437–442.

29. Jadhav U, Mukherjee K, Thakur H. Usage of complementary and alternative medicine among severe hemophilia A patients in India. J Evid Based Complementary Altern Med. 2013; 18:191–197.